




## MyCell<sup>®</sup> Disease and Diversity Products

Cellular Dynamics International (CDI) offers MyCell<sup>®</sup> Disease and Diversity Products, part of the MyCell Products suite. MyCell Disease and Diversity Products are human induced pluripotent stem (iPS) cell-derived differentiated cells that are produced on a variety of disease and diversity background genotypes—resulting in relevant phenotypes for drug discovery, toxicity testing, and disease modeling applications.

MyCell Disease and Diversity Products overcome many limitations of current cell culture lines. CDI's proprietary

manufacturing methods enable industrial-quantity production of highly purified, strongly predictive cells that serve as powerful cellular models capable of driving disease research, drug development, and cell-based therapeutics programs.



▲ **Figure 1: MyCell Disease and Diversity Products Provide Assay-ready Differentiated Cells, Saving You Time**  
*Choose differentiated cells (e.g. cardiac, neural, skeletal) manufactured from a growing list of specific phenotype/genotype iPS cells derived from donors or genetically engineered to represent a specific donor.*

### Advantages

- **Unparalleled access:** iPS cell-derived differentiated human cells are available to study:
  - Induced disease phenotypes
  - Innate disease genotypes of inherited disorders
  - Infectious disease resistance/susceptibility
- **Ready to use:** MyCell Disease and Diversity Products are assay-ready with no differentiation required.
- **Wide variety:** Choose from a multitude of starting backgrounds.
- **Confidence in your results:** Isogenic controls are available.

## Ordering Information

MyCell Disease and Diversity Products are available as multiple cell types (Table 1) produced with background genotypes (Table 2). When ordering, provide both the Catalog # for the cell type and the Clone ID for the cell line.

Don't see what you need? Visit [www.cellulardynamics.com/ddp](http://www.cellulardynamics.com/ddp) to search for newly available cell types and background genotypes.

In addition, CDI can produce iPS cells from customer-defined samples. Visit [www.cellulardynamics.com/mycell](http://www.cellulardynamics.com/mycell) to learn more.

**Table 1**

Cell Type	Catalog # (Viable Cells)
Cardiomyocytes	DDP-CMC-0.5X ( $\geq 2.0 \times 10^6$ ), DDP-CMC-1X ( $\geq 4.0 \times 10^6$ )
Neurons	DDP-NRC-0.5X ( $\geq 2.0 \times 10^6$ ), DDP-NRC-1X ( $\geq 4.0 \times 10^6$ )
DopaNeurons*	DDP-DNC-0.5X ( $\geq 2.5 \times 10^6$ ), DDP-DNC-1X ( $\geq 5.0 \times 10^6$ )
Hepatocytes	DDP-HCC-0.5X ( $\geq 4.5 \times 10^6$ ), DDP-HCC-1X ( $\geq 9.0 \times 10^6$ )
Skeletal Myoblasts	DDP-SKM-0.5X ( $\geq 4.0 \times 10^6$ ), DDP-SKM-1X ( $\geq 8.0 \times 10^6$ )
Endothelial Cells	DDP-ENC-0.5X ( $\geq 0.5 \times 10^6$ ), DDP-ENC-1X ( $\geq 1.0 \times 10^6$ )

\* Dopaminergic neurons

**Table 2**

Clone ID	Disease Description	Genotypic Characterization
01178.103	Hypertrophic cardiomyopathy 1 (OMIM: 192600)	MYH7 mutation R403Q. Female
01434.738	Cardiac arrhythmia, BRGDA1 (OMIM: 600163.0004)	SCN5A mutation T1620M, heterozygous. Female
01434.748	Cardiac arrhythmia, BRGDA3 (OMIM: 114205.0003)	CACNA1C loss of function missense mutation G490R, heterozygous. Female
01279.730	Rett syndrome (OMIM: 312750)	MeCP2 knockout mutation, X-chromosome, hemizygous. Male
01279.A32	Alzheimer's disease, early onset (OMIM: 104760.0022)	APP mutation A673V, heterozygous. Male
01279.A27	Alzheimer's disease, protection from (OMIM: 104760.00023)	APP mutation A673T (Icelandic allele) homozygous. Male
01434.751	Amyotrophic lateral sclerosis 1 (OMIM: 147450.0008)	SOD1 mutation G94A, heterozygous. Female
01279.753	Parkinson's disease 1 (OMIM: 163890.0001)	SNCA mutation A53T, homozygous. Male
01177.103	Drug induced liver injury – DILI reaction to isoniazid (OMIM: Not available)	Isoniazid induced DILI
01173.756	Limb-girdle muscular dystrophy type 2 M (OMIM: 611588)	FKRP gene mutation L276I (c.826 C>A), homozygous. Male
01175.757	Limb-girdle muscular dystrophy type 1 B (OMIM: 613205)	LMNA mutation R249W (c.745 C>T), heterozygous. Male
01279.107	Healthy individual (OMIM: Not available)	Apparently healthy, normal. Male

## For More Information

### Cellular Dynamics International, Inc.

525 Science Drive  
Madison, WI 53711 USA

(608) 310-5100 | Toll-free US (877) 310-6688  
[sales@cellulardynamics.com](mailto:sales@cellulardynamics.com)  
[www.cellulardynamics.com](http://www.cellulardynamics.com)

## CDI Products & Services

### iCell® Products

Provide access to biologically relevant, human iPS cells for disease modeling, drug discovery, toxicity testing, and regenerative medicine. CDI's rapidly growing portfolio of iCell products includes human cardiomyocytes, neurons, hepatocytes, endothelial cells, astrocytes, hematopoietic progenitor cells, skeletal myoblasts, dopaminergic neurons, and others.

Visit the CDI website for the most current list of supported cell types.

### MyCell Products

Include differentiated cells produced from disease-associated iPS cell lines, as well as iPS cell reprogramming, genetic engineering, and differentiation from customer-defined samples.

### iCertification Training Programs

Master the use of iCell products by completing an iCertification Training Program. Attendees receive in-depth, interactive training on the handling and application of iCell products on cutting-edge technologies.

